Literature DB >> 23524342

Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.

Zhili Xu1, Qi Qiu, Jie Tian, Jeffrey S Smith, Gina M Conenello, Takashi Morita, Andrew P Byrnes.   

Abstract

Adenovirus type 5 (Ad5) specifically binds coagulation factor X (FX), and FX is normally essential for intravenously injected Ad5 vectors to transduce the liver. We demonstrate that the ability of FX to enhance liver transduction by Ad5 vectors is due to an unexpected ability of FX to protect Ad5 from attack by the classical complement pathway. In vitro, naive mouse serum neutralized Ad5 when FX was blocked from binding Ad5. This neutralization was mediated by natural IgM and the classical complement pathway. In vivo, FX was essential for Ad5 vectors to transduce the livers of wild-type mice, but FX was not required for liver transduction in mice that lack antibodies, C1q or C4. We conclude that Ad5 recruits FX as a defense against complement and that the sensitivity of Ad5 to inactivation by complement must be taken into account when designing vectors for systemic gene therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23524342     DOI: 10.1038/nm.3107

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  54 in total

1.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

Review 2.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

Review 3.  Complement: an efficient sword of innate immunity.

Authors:  Günter Rambach; Reinhard Würzner; Cornelia Speth
Journal:  Contrib Microbiol       Date:  2008

4.  Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein.

Authors:  H Atoda; M Ishikawa; H Mizuno; T Morita
Journal:  Biochemistry       Date:  1998-12-15       Impact factor: 3.162

5.  Novel anticoagulants for flow cytometric analysis of live leucocytes in whole blood.

Authors:  D A McCarthy; M G Macey
Journal:  Cytometry       Date:  1996-03-01

6.  D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin.

Authors:  C Kettner; E Shaw
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

7.  Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector.

Authors:  Zhi-Li Xu; Hiroyuki Mizuguchi; Akiko Ishii-Watabe; Eriko Uchida; Tadanori Mayumi; Takao Hayakawa
Journal:  J Control Release       Date:  2002-05-17       Impact factor: 9.776

8.  Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum.

Authors:  D P Beebe; N R Cooper
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

9.  Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus.

Authors:  J Chen; M Trounstine; F W Alt; F Young; C Kurahara; J F Loring; D Huszar
Journal:  Int Immunol       Date:  1993-06       Impact factor: 4.823

10.  Tropism-modification strategies for targeted gene delivery using adenoviral vectors.

Authors:  Lynda Coughlan; Raul Alba; Alan L Parker; Angela C Bradshaw; Iain A McNeish; Stuart A Nicklin; Andrew H Baker
Journal:  Viruses       Date:  2010-10-13       Impact factor: 5.818

View more
  82 in total

Review 1.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

2.  FX and host defense evasion tactics by adenovirus.

Authors:  Andrew H Baker; Stuart A Nicklin; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2013-06       Impact factor: 11.454

3.  Platelet-macrophage partnership in innate immunity and inflammation.

Authors:  Alberto Mantovani; Cecilia Garlanda
Journal:  Nat Immunol       Date:  2013-08       Impact factor: 25.606

4.  Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting.

Authors:  Franziska Jönsson; Claudia Hagedorn; Florian Kreppel
Journal:  J Vis Exp       Date:  2018-10-26       Impact factor: 1.355

5.  Coagulation factor defends adenovirus from immune attack.

Authors:  Glen R Nemerow
Journal:  Nat Med       Date:  2013-04       Impact factor: 53.440

Review 6.  Multiple roles of the coagulation protease cascade during virus infection.

Authors:  Silvio Antoniak; Nigel Mackman
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

Review 7.  Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.

Authors:  Franziska Jönsson; Florian Kreppel
Journal:  Virus Genes       Date:  2017-07-28       Impact factor: 2.332

Review 8.  Interactions of viruses and the humoral innate immune response.

Authors:  Bailey E Maloney; Krishani Dinali Perera; Danielle R D Saunders; Naemi Shadipeni; Sherry D Fleming
Journal:  Clin Immunol       Date:  2020-02-04       Impact factor: 3.969

9.  Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.

Authors:  Sergey A Kaliberov; Lyudmila N Kaliberova; Zhi Hong Lu; Meredith A Preuss; Justin A Barnes; Cecil R Stockard; William E Grizzle; Jeffrey M Arbeit; David T Curiel
Journal:  Virology       Date:  2013-10-15       Impact factor: 3.616

10.  Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.

Authors:  Anne K Zaiss; Erin M Foley; Roger Lawrence; Lina S Schneider; Hamidreza Hoveida; Patrick Secrest; Arthur B Catapang; Yu Yamaguchi; Ramon Alemany; Dmitry M Shayakhmetov; Jeffrey D Esko; Harvey R Herschman
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.